Merck's Grastek gets first North American approval
This article was originally published in Scrip
Executive Summary
Competition in the North American oral seasonal allergy market is hotting up, with Merck & Co scoring its first approval for Grastek, its treatment for Timothy grass pollen allergy, in Canada.